SynthesisPathogens and global health2023
Praziquantel efficacy, urinary and intestinal schistosomiasis reinfection - a systematic review.
Synthesis in Pathogens and global health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Glycan remodelling of live adult Schistosoma mansoni worms by chemical inhibition of α-mannosidases.International journal for parasitology · 2026Article
- TRPtracker: a community database for monitoring praziquantel sensitivity at TRPMInternational journal for parasitology. Drugs and drug resistance · 2026Article
- Impact of pre-treatment food on praziquantel absorption, metabolism, treatment-associated side effects, and drug efficacy: a systematic review and meta-analysis protocol.Systematic reviews · 2026Article
- Crystal structure of Schistosoma mansoni cathepsin D1 in complex with a nanobody reveals the conformation of the propeptide-bound state.Acta crystallographica. Section D, Structural biology · 2026Article
- Mass drug administration of praziquantel lowers the susceptibility of school-aged children toFrontiers in immunology · 2026Article
- Schistosomiasis in Yemen: Focal Persistence, Possible Resurgence, and Challenges to Elimination.Research and reports in tropical medicine · 2026Review
- TRPtracker: a community database for monitoring praziquantel sensitivity at TRPMbioRxiv : the preprint server for biology · 2025Article
- Effects of an integrated intervention on schistosomiasis prevalence in a rural area of Tanzania.PLoS neglected tropical diseases · 2025Article
- High-Throughput Screens of Repurposing Hub and DOS Chemical Libraries Reveal Compounds with Novel and Potent Inhibitory Activity Against the Essential Non-Neuronal Acetylcholinesterase ofInternational journal of molecular sciences · 2025Article
- Molluscicidal and Schistosomicidal Activities of 2-(1Pharmaceuticals (Basel, Switzerland) · 2025Article
- Priority knowledge gaps for schistosomiasis research and development in the World Health Organization Africa Region.Infectious diseases of poverty · 2025Article
- Factors contributing to helminth prevalence after repeated mass administration of medicines in Anambra State, Nigeria.Scientific reports · 2025Article
- Urogenital schistosomiasis in schoolchildren in the lake zones of Kankossa and Oued Rawdha, southern Mauritania: The first parasitological and malacological survey.PLoS neglected tropical diseases · 2024Article
- Article
- Identification of potent schistosomicidal compounds predicted as type II-kinase inhibitors againstFrontiers in parasitology · 2024Article
- Praziquantel resistance in schistosomes: a brief report.Frontiers in parasitology · 2024Review
- Article
- Unisexual infection withFrontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Praziquantel (PZQ) has been extensively used as the drug of choice for the treatment of schistosomiasis on account of its safety and effectiveness against all major forms of schistosomiasis. However, low cure rate, reduced susceptibility of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.